Literature DB >> 31510897

Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile.

Babak B Navi1,2, Ryna Mathias1, Carla P Sherman1, Julia Wolfe2, Hooman Kamel1, Scott T Tagawa3, Ashish Saxena3, Allyson J Ocean3, Costantino Iadecola1, Lisa M DeAngelis1,2, Mitchell S V Elkind4,5, Heather Hull6, Glen C Jickling6, Frank R Sharp6, Bradley P Ander6, Boryana Stamova6.   

Abstract

Background and Purpose- Comorbid cancer is common in patients with acute ischemic stroke (AIS). As blood mRNA profiles can distinguish AIS mechanisms, we hypothesized that cancer-related AIS would have a distinctive gene expression profile. Methods- We evaluated 4 groups of 10 subjects prospectively enrolled at 3 centers from 2009 to 2018. This included the group of interest with active solid tumor cancer and AIS and 3 control groups with active cancer only, AIS only, or vascular risk factors only. Subjects in the AIS-only and cancer-only groups were matched to subjects in the cancer-stroke group by age, sex, and cancer type (if applicable). Subjects in the vascular risk factor group were matched to subjects in the cancer-stroke and stroke-only groups by age, sex, and vascular risk factors. Blood was drawn 72 to 120 hours after stroke. Total RNA was processed using 3' mRNA sequencing. ANOVA and Fisher least significant difference contrast methods were used to estimate differential gene expression between groups. Results- In the cancer-stroke group, 50% of strokes were cryptogenic. All groups had differentially expressed genes that could distinguish among them. Comparing the cancer-stroke group to the stroke-only group and after accounting for cancer-only genes, 438 genes were differentially expressed, including upregulation of multiple genes/pathways implicated in autophagy signaling, immunity/inflammation, and gene regulation, including IL (interleukin)-1, interferon, relaxin, mammalian target of rapamycin signaling, SQSTMI1 (sequestosome-1), and CREB1 (cAMP response element binding protein-1). Conclusions- This study provides evidence for a distinctive molecular signature in blood mRNA expression profiles of patients with cancer-related AIS. Future studies should evaluate whether blood mRNA can predict detection of occult cancer in patients with AIS. Clinical Trial Registration- URL: https://clinicaltrials.gov. Unique identifier: NCT02604667.

Entities:  

Keywords:  gene expression; humans; neoplasms; risk factors; stroke

Mesh:

Substances:

Year:  2019        PMID: 31510897      PMCID: PMC6817410          DOI: 10.1161/STROKEAHA.119.026143

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

Review 1.  Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update.

Authors:  Robert G Hart; Luciana Catanese; Kanjana S Perera; George Ntaios; Stuart J Connolly
Journal:  Stroke       Date:  2017-03-06       Impact factor: 7.914

2.  Arterial thromboembolic events preceding the diagnosis of cancer in older persons.

Authors:  Babak B Navi; Anne S Reiner; Hooman Kamel; Costantino Iadecola; Peter M Okin; Scott T Tagawa; Katherine S Panageas; Lisa M DeAngelis
Journal:  Blood       Date:  2018-12-21       Impact factor: 22.113

3.  The intracerebral hemorrhage blood transcriptome in humans differs from the ischemic stroke and vascular risk factor control blood transcriptomes.

Authors:  Boryana Stamova; Bradley P Ander; Glen Jickling; Farah Hamade; Marc Durocher; Xinhua Zhan; Da Zhi Liu; Xiyuan Cheng; Heather Hull; Alan Yee; Kwan Ng; Natasha Shroff; Frank R Sharp
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-13       Impact factor: 6.200

Review 4.  DNA damage response genes and the development of cancer metastasis.

Authors:  Constantinos G Broustas; Howard B Lieberman
Journal:  Radiat Res       Date:  2014-01-07       Impact factor: 2.841

5.  Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke.

Authors:  Y Gon; M Sakaguchi; J Takasugi; T Kawano; H Kanki; A Watanabe; N Oyama; Y Terasaki; T Sasaki; H Mochizuki
Journal:  Eur J Neurol       Date:  2016-12-27       Impact factor: 6.089

6.  First-ever stroke as initial presentation of systemic cancer.

Authors:  Fabio Silvio Taccone; Sandrine M Jeangette; Serge A Blecic
Journal:  J Stroke Cerebrovasc Dis       Date:  2008 Jul-Aug       Impact factor: 2.136

7.  p62/SQSTM1 regulates cellular oxygen sensing by attenuating PHD3 activity through aggregate sequestration and enhanced degradation.

Authors:  Krista Rantanen; Juha-Pekka Pursiheimo; Heidi Högel; Petra Miikkulainen; Jari Sundström; Panu M Jaakkola
Journal:  J Cell Sci       Date:  2013-01-23       Impact factor: 5.285

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

9.  CREB controls cortical circuit plasticity and functional recovery after stroke.

Authors:  L Caracciolo; M Marosi; J Mazzitelli; S Latifi; Y Sano; L Galvan; R Kawaguchi; S Holley; M S Levine; G Coppola; C Portera-Cailliau; A J Silva; S T Carmichael
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 17.694

Review 10.  Targeting Inflammation in Cancer Prevention and Therapy.

Authors:  Jelena Todoric; Laura Antonucci; Michael Karin
Journal:  Cancer Prev Res (Phila)       Date:  2016-11-10
View more
  3 in total

Review 1.  Cancer and Embolic Stroke of Undetermined Source.

Authors:  Babak B Navi; Scott E Kasner; Mitchell S V Elkind; Mary Cushman; Oh Young Bang; Lisa M DeAngelis
Journal:  Stroke       Date:  2021-01-28       Impact factor: 7.914

Review 2.  Role of Glial Cell-Derived Oxidative Stress in Blood-Brain Barrier Damage after Acute Ischemic Stroke.

Authors:  Xiaoyan Hu; Yanping Wang; Weihong Du; Li-Jun Liang; Wei Wang; Xinchun Jin
Journal:  Oxid Med Cell Longev       Date:  2022-09-02       Impact factor: 7.310

3.  Stroke Exacerbates Cancer Progression by Upregulating LCN2 in PMN-MDSC.

Authors:  Tingting Huang; Yan Li; Yuxi Zhou; Bingwei Lu; Yueman Zhang; Dan Tang; Yu Gan; Zhengzhou He; Zengai Chen; Weifeng Yu; Peiying Li
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.